One of the main causes of failure in the treatment of breast cancer is the intrinsic presence of, or development of, drug resistance by the cancer cells. Recent studies on the mechanisms of cancer drug resistance have yielded important information highlighting both how tumour cells may escape these therapeutic constraints and that drug resistance may further impinge on tumour cell functions that may ultimately promote an adverse cell phenotype. New targets have been identified with potential therapeutic applications in resistant breast cancer leading to the subsequent evaluation of inhibitors of these targets in preclinical studies. Importantly, there is increasing evidence from such studies demonstrating the benefit of novel combination strategies as potential avenues for future drug regimens. Written by experts in the subject area, this book covers the molecular details and functional consequences of endocrine resistance in breast cancer with particular emphasis on the future applications of novel drug combinations that may be utilized to circumvent resistance and improve anti-tumour effects. This book represents a timely publication in the field of breast cancer research, providing current knowledge in the area of drug resistance and will be important reading material for clinicians and researchers alike.

Inhalt
Experimental Endocrine Resistance: Concepts and Strategies.- Transcriptional Coactivators and Corepressors in Endocrine Response and Resistance in Breast Cancer.- The Re-Expression of Estrogen Receptor in Estrogen Receptor-Negative Breast Cancer and Restoration of Anti-Estrogen Responses.- The Dark Side of Antihormonal Action in Breast Cancer.- Influence of the Tumour Microenvironment.- Are Stem-Like Cells Responsible for Resistance to Therapy in Breast Cancer?.- HSP90 Inhibition as an Anticancer Strategy: Novel Approaches and Future Directions.- Adverse Features of Acquired Antihormone Resistance and Their Targeting.- Identifying Modifiers of Tamoxifen Sensitivity Using High-Throughput Genetic and Chemical Screens.- Endocrine Resistance in Breast Cancer- Where Are We NowWith Intelligent Combination Therapies?.